What Ferrograd-Fol Treats: Main Uses and Benefits

Ferrograd-Fol is an established combination product used to address deficiencies of certain essential micronutrients. It is primarily used for the therapeutic and prophylactic management of specific nutritional deficits.

Quick Facts on Use

• Targeted Deficit: Assists in the replenishment of iron and folic acid stores.
• Primary Indication: Used in the management of iron-deficiency anemia.
• Secondary Use: Indicated to prevent anemia related to folic acid deficiency.

This medication is typically prescribed for individuals who have been diagnosed with an iron deficiency or iron-deficiency anemia, often compounded by a simultaneous need for folic acid supplementation. The therapeutic objective is to support the body's processes for forming red blood cells (erythropoiesis) and to help maintain normal blood oxygen transport capabilities. It is commonly utilized for prophylaxis and treatment during stages of increased nutritional requirement, such as during pregnancy, under the guidance of a healthcare professional. This combination of vital components works to ensure that both iron and folic acid levels are adequately supported to meet the body's physiological demands.

Regulatory References

1. NIH MedlinePlus guidance on iron supplementation

Who Can and Cannot Use Ferrograd-Fol?

The population eligibility for Ferrograd-Fol is strictly defined by regulatory authorities and is based on the type of anemia, iron status, age, and pre-existing medical conditions. The medicine is approved for use in adults and the elderly for diagnosed iron and folic acid deficiencies.

Contraindicated Populations (Must Not Use)

Ferrograd-Fol is strictly contraindicated in individuals with conditions that elevate the risk of iron overload, such as haemochromatosis or iron overload syndromes. It must also be avoided by patients with megaloblastic anaemia due to primary Vitamin B12 deficiency or any undiagnosed anaemia, as the folic acid component can mask the symptoms of Vitamin B12 deficiency. Patients with certain gastrointestinal conditions, including intestinal obstruction or diverticular disease, are also prohibited from use.

Restricted Use and Age Eligibility

The medicine is generally not recommended for children under 12 years of age. Use during the first 13 weeks of pregnancy is restricted and requires specific medical consultation; it is indicated for use after the first trimester. Elderly patients or those with swallowing difficulties require cautious evaluation, as the sustained-release tablet may pose a risk due to delayed intestinal transit.

Ferrograd-Fol's interaction profile is primarily characterized by pharmacokinetic interference, where the iron component reduces the systemic exposure of several co-administered oral medications.

Official Interaction Statements

Classification	Interacting Substances/Conditions
Contraindicated Combinations	Parenteral Iron preparations and Mineral Oil. Also, high-dose folic acid in patients with undiagnosed pernicious anemia (Vitamin B12 deficiency) is prohibited as it may obscure the diagnosis.
Exposure-Altering Agents	Quinolones (e.g., Ciprofloxacin), Tetracyclines, Levothyroxine, Levodopa, Methyldopa, Bisphosphonates, and Mycophenolate Mofetil have reduced absorption when co-administered with iron salts.
Anticonvulsant Interactions	The folic acid component may reduce the plasma concentration of certain anticonvulsants, including Phenytoin and Phenobarbital.

Timing and Dietary Constraints

Mandatory timing separation rules are documented to mitigate reduced absorption. Oral iron should not be ingested within one hour before or four hours after Quinolone anti-infective agents, and administration with Tetracycline antibiotics should be separated by at least two to three hours. Antacids and other mineral supplements (containing Calcium, Magnesium, or Zinc) also impair iron absorption, requiring separation by at least two hours. Specific foods and drinks, including tea, coffee, milk, and wholegrain cereals, are documented to decrease iron absorption and should not be consumed within one to two hours of taking the product. Additionally, chronic alcohol consumption is documented to decrease folic acid absorption and increase its elimination.

Core Mechanism: Replenishing Essential Substrates

This domain covers the primary biological interaction: the active ingredients function as essential substrates, delivering ferrous iron ( Fe^2+) and folic acid to be absorbed in the gastrointestinal tract and enter systemic circulation. This is critical because these components are the fundamental precursors required by key biosynthetic pathways for macromolecule synthesis.

Converging on the Erythropoietic Cascade

The active ingredients converge within the hematopoietic system, particularly in the bone marrow, to enable red blood cell (RBC) maturation and quality. Folate cofactors are essential for DNA synthesis, enabling proper cell division, while iron is incorporated into heme to form functional hemoglobin.

Resulting Physiological Effect: Boosting Oxygen Transport

The action on the red blood cell production pathway results in the systemic physiological outcome: the release of a greater quantity of functional, hemoglobin-rich RBCs. This action directly and sustainably elevates the blood's oxygen-carrying capacity by increasing the concentration of functional hemoglobin, which supports systemic oxygenation.

Administration Guidelines for Ferrograd-Fol

Ferrograd-Fol is an oral preparation of ferrous sulfate and folic acid, designed as a prolonged-release tablet. The administration instructions are structured to ensure the slow, sustained release of the iron component is maintained, which is a key feature of the formulation.

Dosage and Frequency

The standard regimen for therapeutic and prophylactic use in adults, including the elderly, is one tablet daily. Each tablet contains 325 mg of dried ferrous sulfate (equivalent to 105 mg of elemental iron) and 0.35 mg of folic acid. Use in children under 12 years of age is not recommended.

Administration Method

Ferrograd-Fol tablets must be swallowed whole with water. It is a critical instruction that the tablet must not be sucked, chewed, or kept in the mouth. This restriction is in place to prevent the elemental iron from causing localized irritation and ulcerations.

Timing and Duration

Administration may occur before meals for optimal absorption, or during meals if taking it on an empty stomach causes gastrointestinal upset. In the event of a missed dose, the next scheduled dose should be taken as planned; taking more than one tablet per day is not permitted to compensate for a missed dose. Treatment duration often continues for three to six months to ensure the body’s iron reserves are fully replenished.

Research Evidence: Overview of Studies for Ferrograd-Fol

---

Evidence for Deficiency Correction and Anemia Treatment

The core research base for this combination preparation involves studies that explored its presence in individuals with iron and folate deficiencies, which are conditions where symptoms may vary in intensity. The research was primarily conducted using Randomized Controlled Trials (RCTs) and is supported by evidence derived from the long history of clinical and research use of the iron component (ferrous sulfate). These studies monitored changes in key hematological status indicators, such as hemoglobin and ferritin levels, which reflect systemic or functional imbalance related to blood formation.

In these research scenarios, the findings describe patterns related to changes in blood marker measurements over defined time intervals. This evidence contributes to the broader evidence landscape used by health regulators to understand how patients with confirmed deficiencies evolve during the study period.

However, the existing research is limited as the evidence primarily focused on measured changes in blood markers over the short-term. Long-term effects are not fully established regarding the maintenance of these healthy blood levels after the initial study period concludes. Furthermore, comparative evidence is lacking to clarify whether this specific combination product differs in measured outcomes from receiving iron and folic acid separately outside of specific prophylactic contexts.

---

Research Focus on Pregnancy and Maternal Health

Research on the use of combination iron and folic acid during pregnancy is extensive, featuring many large Systematic Reviews that synthesize the data from numerous RCTs. These studies were applied in research contexts exploring the prophylaxis and treatment of maternal anemia, a condition often characterized by functional limitations. Researchers explored outcomes related to the mother's hematological status and the related research on fetal outcomes, including the risk of neural tube defects (NTDs), which is an outcome linked specifically to the folic acid component.

Research describes patterns where supplementation was associated with a lower measured incidence of maternal anemia and iron deficiency by the time of delivery. The research base for the folic acid component studies explored patterns concerning the measured incidence of neural tube defects when supplementation occurred before and during early pregnancy.

Despite this body of evidence, the certainty remains low regarding outcomes related to maternal death or the incidence of severe maternal anemia. Research also provides limited information for long-term outcomes for the child; follow-up durations were limited primarily to the delivery period.

Key Studies & References Ferrous Sulfate and Folic Acid: Drug Information (Authoritative Monograph)

Common questions about Ferrograd-Fol (FAQ)

Q: What is Ferrograd-Fol?

Ferrograd-Fol is a medicinal product containing two active ingredients: ferrous sulfate (an iron supplement) and folic acid (a B vitamin). It is typically studied for use in conditions where a deficiency of both iron and folic acid is present.

Q: What are the active ingredients in Ferrograd-Fol?

The primary active ingredients are a form of iron (ferrous sulfate) and folic acid. These substances are known to be essential nutrients that play a role in the body's normal production of red blood cells.

Q: How should I store Ferrograd-Fol?

This product should be stored in a cool, dry place, away from direct light and moisture. It is important to keep the product out of the sight and reach of children, as iron supplements can be harmful if taken accidentally.

Ferrograd-Fol tablets must be stored and handled according to specific conditions defined by regulatory authorities to ensure stability and safety.

Storage & Disposal Scope	Official Regulatory Statement
Storage Temperature	Do not store the tablets above 25 C.
Protection Requirements	Must be protected from light and stored in the original package.
Child-Safety Rule	Keep out of the sight and reach of children (mandatory due to iron poisoning risk).
Expiry Date	Do not use the medicine after the expiry date printed on the packaging.
Disposal Instructions	Do not throw away unused or expired medicine via wastewater or household waste; ask a pharmacist for safe disposal instructions.

These official requirements ensure the medicine remains effective until the expiry date and prevent environmental contamination, while strictly adhering to the critical instruction to keep the iron-containing product inaccessible to children.